In summary, GLP-1 RAs demonstrated superior cardiovascular benefits compared to SGLT2 inhibitors in reducing the risk of cardiovascular events, SHF, and strokes in diabetic patients with HFpEF, as shown in Figs 2 and 3. Here, SLC5A2 is linked to Stroke.